{"version":1,"type":"rich","provider_name":"Libsyn","provider_url":"https:\/\/www.libsyn.com","height":90,"width":600,"title":"Maintaining Weight Loss with Tirzepatide; the new Dyslipidemia Guidelines; Sacubitril\/Valsartan &amp; HFpEF &amp; Functional MR; Digitoxin &amp; Heart Failure","description":" In this week\u2019s View, Dr. Eagle\u202fexamines&amp;nbsp;recent research into&amp;nbsp;maintaining&amp;nbsp;weight loss with tirzepatide.&amp;nbsp;He then&amp;nbsp;offers insights into the new dyslipidemia&amp;nbsp;guidelines,&amp;nbsp;including addressing reproductive and hormone risk factors in&amp;nbsp;cardiovascular risk assessment.&amp;nbsp;Next, Dr. Eagle&amp;nbsp;looks&amp;nbsp;at the use of&amp;nbsp;sacubitril\/valsartan&amp;nbsp;to improve exercise tolerance&amp;nbsp;in patients with&amp;nbsp;heart failure with reduced ejection fraction (HFpEF)&amp;nbsp;and functional&amp;nbsp;mitral regurgitation (MR).&amp;nbsp;Finally,\u202fDr. Eagle&amp;nbsp;summarizes&amp;nbsp;a new study on the use of&amp;nbsp;digitoxin and&amp;nbsp;digoxin&amp;nbsp;in patients with heart failure.&amp;nbsp;   Subscribe to Eagle\u2019s Eye View\u202f\u202f&amp;nbsp;  ","author_name":"Eagle's Eye View: Your Weekly CV Update From ACC.org","author_url":"http:\/\/www.acc.org","html":"<iframe title=\"Libsyn Player\" style=\"border: none\" src=\"\/\/html5-player.libsyn.com\/embed\/episode\/id\/41439805\/height\/90\/theme\/custom\/thumbnail\/yes\/direction\/forward\/render-playlist\/no\/custom-color\/88AA3C\/\" height=\"90\" width=\"600\" scrolling=\"no\"  allowfullscreen webkitallowfullscreen mozallowfullscreen oallowfullscreen msallowfullscreen><\/iframe>","thumbnail_url":"https:\/\/assets.libsyn.com\/secure\/content\/202353725"}